Product Images Topiramate
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 4 images provide visual information about the product associated with Topiramate NDC 68071-1612 by Nucare Pharmaceuticals,inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
PDP - 68071 1612 6
This medication is Topiramate 100mg in the form of #60 tablets per bottle with lot numbers 600000 and 000000. The National Drug Code (NDC) for both lots is 68071-1612-06. The manufacturer's NDC is 47335-711-86 and the expiration date is 00-00. The product can only be obtained with a prescription and must be kept out of reach of children. The user is encouraged to call their doctor for advice about side effects and to report side effects to the FDA. The medication should be stored at a controlled temperature between 59-86°F.*
chemical-structure - chemical structure
figure-1jpg - figure 1
The text describes a graph showing the cumulative rates for time to the first seizure in patients taking topiramate at 50 mg/day (sample size N=234) and topiramate at 400 mg/day (sample size N=236). The graph indicates that the group taking the higher dose of topiramate experienced a lower rate of seizures over time. The p-value for the comparison between the two groups is 0.0002. The x-axis shows time in days (from 0 to 500), and the y-axis shows the cumulative rate of seizures (from 0% to 100%).*
figure-2 - figure 2
This appears to be a table or chart with information related to a medication called Topamax and its effectiveness in treating migraines. The table displays the dosages tested (100mg/day and 200mg/day) and the number of participants in each group (115, 119, 125, 120, 112, and 117). The data in the chart seems to show the change from baseline to the double-blind phase in average monthly migraine periods with a success criterion of p<0.010 for Study 1 and p <0.001 for Study 2. It appears to be a quantitative analysis of clinical trial results for Topamax, but without more context, it is difficult to determine the full significance or implications of the data displayed.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.